Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Notes Payables (2016 - 2023)

Historic Notes Payables for Fortress Biotech (FBIO) over the last 10 years, with Q1 2023 value amounting to $3.0 million.

  • Fortress Biotech's Notes Payables changed N/A to $3.0 million in Q1 2023 from the same period last year, while for Mar 2023 it was $3.0 million, marking a year-over-year change of. This contributed to the annual value of $2.9 million for FY2022, which is 26305.42% up from last year.
  • Per Fortress Biotech's latest filing, its Notes Payables stood at $3.0 million for Q1 2023.
  • In the past 5 years, Fortress Biotech's Notes Payables registered a high of $86.0 million during Q2 2020, and its lowest value of $812000.0 during Q4 2021.
  • In the last 5 years, Fortress Biotech's Notes Payables had a median value of $30.9 million in 2020 and averaged $41.9 million.
  • Its Notes Payables has fluctuated over the past 5 years, first plummeted by 9360.21% in 2021, then soared by 26305.42% in 2022.
  • Quarter analysis of 5 years shows Fortress Biotech's Notes Payables stood at $7.2 million in 2019, then surged by 611.81% to $51.4 million in 2020, then tumbled by 98.42% to $812000.0 in 2021, then skyrocketed by 263.05% to $2.9 million in 2022, then increased by 1.76% to $3.0 million in 2023.
  • Its Notes Payables was $3.0 million in Q1 2023, compared to $2.9 million in Q4 2022 and $812000.0 in Q4 2021.